Skip to main content
. 2025 Mar 27;19:2315–2327. doi: 10.2147/DDDT.S515741

Table 4.

Harms

Variables Placebo Group (n=178) S-Ketamine Group (n=178) RR (95% CI) P value
Nausea and vomiting 32 (18%) 34 (19%) 1.01 (0.69, 1.64) 0.785
Respiratory depression 2 (1.1%) 2 (1.1%) 1.00 (0.14, 7.02) >0.999
Hypertension 8 (4.5%) 15 (8.4%) 1.88 (0.82, 4.31) 0.131
Hypotension 2 (1.1%) 3 (1.7%) 1.50 (0.25, 8.87) >0.999
Tachycardia 3 (1.7%) 4 (2.2%) 1.33 (0.30, 5.87) >0.999
Bradycardia 2 (1.1%) 7 (3.9%) 7.00 (0.73, 16.62) 0.177
Deliriuma 8 (4.5%) 10 (5.6%) 1.25 (0.51, 3.01) 0.629
Nightmare 3 (1.7%) 6 (3.4%) 2.00 (0.51, 7.87) 0.311
Agitationb 2 (1.1%) 3 (1.7%) 1.50 (0.25, 8.87) >0.999
Hallucinationc 0 11 (6.2%) NE 0.001
Nerve injury 0 0 NE NE
Wound infection 0 0 NE NE
Deep vein thrombosis 2 (1.1%) 1 (0.6%) 0.50 (0.05, 5.47) >0.999
Pulmonary embolism 0 0 NE NE

Notes: Data is presented as the number of cases (percentage). aDelirium was diagnosed using the Chinese version of the 3D-CAM. The 3D-CAM identifies delirium through a diagnostic algorithm based on the four essential features of delirium: (A) acute changes or fluctuations in mental status; (B) inattention; (C) disorganized thinking; and (D) altered level of consciousness. Diagnosis of delirium requires criteria A and B and either or both criteria C and D. bAgitation was diagnosed using the Riker Sedation-Agitation Scale (SAS), with a score of 5 or higher indicating agitation. cHallucinations encompass auditory, visual, and somatic hallucinations.

Abbreviation: NE, not estimable.